China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..

On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited ("CMS" or the "Group") on the Main Board of the Singapore Exchange ("SGX"), SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner".
More info..

More info..

Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries.
More info..

China Medical Systems, its subsidiary and Kangzhe Pharmaceutical Research and Development (Shenzhen) Limited held a successful roundtable meeting with the State Food and Drug Administration ("SFDA") of China.
More info..

China Medical System Holdings Ltd. (HKSE:0867) expects to release its results for the year ended 31 December 2010 in early March 2011.
More info..